Posted on by admin

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. announced positive topline results from the Phase 2 ELEKTRA study of soticlestat.
( read original story …)